Nuvation Bio (NUVB) shares have caught investor attention following recent trading activity that pushed the stock up more than 50% over the past month. The move has sparked new conversations about the ...

Nuvation Bio (NUVB) has decided to halt the development of NUV-1511, the initial compound in its innovative drug-drug conjugate program. Although NUV-1511, under investigation for solid tumors, was ...

In other recent news, Nuvation Bio Inc. reported third-quarter 2025 earnings that exceeded expectations, with revenue reaching $13.1 million against a forecast of $6.8 million. The earnings per share ...

NEW YORK, November 26, 2025--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that ...

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

The price target increase follows promising results from safusidenib, Nuvation’s drug candidate being tested in a Phase 2 Japanese glioma study. According to Citizens, the drug significantly ...

We recently published 10 Stocks Beating Wall Street at its Own Game. Nuvation Bio Inc. (NYSE:NUVB) is one of the best-performing stocks on Wednesday. Nuvation Bio saw its share prices jump to a new ...

Shares of Nuvation Bio (NUVB) climbed ~48% on Wednesday after B. Riley Securities launched its coverage with a Buy recommendation and a $12 per share target, citing early signs of a successful ...

Investing.com - Nuvation Bio Inc (NYSE:NUVB) received a Buy rating initiation from B.Riley on Wednesday, with analyst Mayank Mamtani setting a $12.00 price target for the biopharmaceutical company.

Nuvation Bio Inc (NUVB) has disclosed a new risk, in the Sales & Marketing category. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom ...

Nuvation Bio has backed off from its plans to directly compare its brain cancer drug to Servier's Voranigo, instead opting to focus on patients who aren’t covered by the approved competitor.